Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan

Abstract Introduction Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This post-marketing surveillance (PMS) is underway to investigate...

Full description

Bibliographic Details
Published in:	Infectious Diseases and Therapy
Main Authors:	Masahiro Kimata, Asuka Watanabe, Yukiko Yanagida, Daisuke Kinoshita, Shinichiroh Maekawa
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-03-01
Subjects:	COVID-19 Japan Molnupiravir Post-marketing Safety
Online Access:	https://doi.org/10.1007/s40121-023-00782-5

Similar Items

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan
by: Shohei Shinozaki, et al.
Published: (2024-01-01)

Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01)

BIOEQUIVALENCE STUDY OF GENERIC MOLNUPIRAVIR IN HEALTHY VOLUNTEERS
by: V. B. Vasilyuk, et al.
Published: (2023-02-01)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
by: Michela Pontolillo, et al.
Published: (2022-09-01)

Can Tremor Be a Rare Side Effect Related to Molnupiravir?
by: Sinan MERMER, et al.
Published: (2022-11-01)

Efficacy and safety of molnupiravir in adult outpatients with COVID-19
by: Natalia Y. Pshenichnaya, et al.
Published: (2023-06-01)

Garlic peel-based carbon quantum dots as a sustainable alternative for the sensitive and green spectrofluorometric quantification of molnupiravir in pharmaceutical capsules
by: Yomna A. Saber, et al.
Published: (2024-12-01)

Degree-Based and Neighborhood Degree Sum-Based Entropy Measures of Molnupiravir
by: Shibsankar Das, et al.
Published: (2025-06-01)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
by: Yuan Bai, et al.
Published: (2022-04-01)

Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial
by: T. N. Komarov, et al.
Published: (2024-03-01)

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo
by: Yuexiang Li, et al.
Published: (2022-05-01)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro
by: Zi-Xin Huang, et al.
Published: (2023-06-01)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
by: Clara Weil, et al.
Published: (2023-08-01)

Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection
by: Hikari Mizutani, et al.
Published: (2022-01-01)

Molnupiravir: From Hope to Epic Fail?
by: Daniele Focosi
Published: (2022-11-01)

Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir
by: Omar Faruk, et al.
Published: (2024-01-01)

Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
by: Ivana I Gmizic, et al.
Published: (2024-05-01)

GS-441524 and molnupiravir are similarly effective for the treatment of cats with feline infectious peritonitis
by: Okihiro Sase, et al.
Published: (2024-07-01)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
by: Ashley Jia Wen Yip, et al.
Published: (2022-06-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
by: Matthew G. Johnson, et al.
Published: (2024-03-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
by: Henrik Berg Rasmussen, et al.
Published: (2023-10-01)

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis
by: Huzaifa Ahmad Cheema, et al.
Published: (2024-06-01)

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders
by: Ting-Hui Liu, et al.
Published: (2024-07-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
by: Ching-Chi Lee, et al.
Published: (2021-10-01)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
by: Divya Teli, et al.
Published: (2023-02-01)

Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
by: Nicolas Salvadori, et al.
Published: (2024-06-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice
by: Gayan Bamunuarachchi, et al.
Published: (2025-10-01)

Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01)

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
by: Julie M. Strizki, et al.
Published: (2023-11-01)

Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression
by: Antonio Vena, et al.
Published: (2022-07-01)

Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis
by: Seyed Hamid Pakzad Moghadam, et al.
Published: (2025-10-01)

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
by: Bahman Amani, et al.
Published: (2024-04-01)

Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review
by: Julia Richmond DiBello, et al.
Published: (2024-05-01)

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
by: Lina Kamal, et al.
Published: (2022-05-01)

Molnupiravir in Combination with Remdesivir for Severe COVID-19 Patients Admitted to Hospital: a Case Series
by: Seyed Mohammad Reza Hashemian, et al.
Published: (2022-04-01)